Genomic and Transcriptomic Profiles Associated with Response to Eribulin and Nivolumab Combination in HER-2-negative Metastatic Breast Cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY(2024)
Key words
Immunotherapy,Eribulin,HER-2-negative metastatic breast cancer,Genomics,Transcriptomics,Biomarker
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined